GALECTIN THERAPEUTICS INC - COM NEW (GALT)

Q2 2018 13F Holders as of 30 Jun 2018

Type / Class
Equity / COM NEW
Total 13F shares
5,574,695
Share change
+592,280
Total reported value
$35,452,254
Put/Call ratio
470%
Price per share
$6.36
Number of holders
66
Value change
+$4,184,678
Number of buys
37
Number of sells
25

Institutional Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q2 2018

As of 30 Jun 2018, GALECTIN THERAPEUTICS INC - COM NEW (GALT) was held by 66 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 5,574,695 shares. The largest 10 holders included VANGUARD GROUP INC, D.A. DAVIDSON & CO., Advisor Group, Inc., BlackRock Inc., SUSQUEHANNA INTERNATIONAL GROUP, LLP, Benchmark Capital Advisors, EAM Investors, LLC, GEODE CAPITAL MANAGEMENT, LLC, EAM Global Investors LLC, and GROUP ONE TRADING, L.P.. This page lists 66 institutional shareholders reporting positions in this security for the Q2 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.